MOUNTAIN VIEW, Calif. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has commenced an underwritten public offering of $75 million of its common stock.  In connection with this offering, ChemoCentryx plans to grant the underwriters a 30-day option to

MOUNTAIN VIEW, Calif. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Tuesday October 2, 2018 at 1:40 p.m. ET .

MOUNTAIN VIEW, Calif. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in September: 20 th Annual Rodman & Renshaw Global Investment

-- Completed patient enrollment in Phase III ADVOCATE trial of avacopan in ANCA-associated vasculitis -- -- Ongoing clinical trials with avacopan in C3 Glomerulopathy (C3G) and CCX140 in Focal Segmental Glomerulosclerosis (FSGS), diseases with no approved therapies -- -- Launch of clinical

MOUNTAIN VIEW, Calif. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's second quarter 2018 financial results will be released after market close on Thursday, August 9, 2018 . ChemoCentryx executive management will host a conference call and

MOUNTAIN VIEW, Calif. , May 30, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in June: Jefferies 2018 Global Healthcare Conference Corporate

MOUNTAIN VIEW, Calif. , May 23, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced two upcoming presentations during the 55th European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress , being held in collaboration with the Danish Society

-- Patient enrollment in Phase III ADVOCATE trial of avacopan in the treatment of ANCA-associated vasculitis exceeds 85%; Conditional Marketing Authorization (CMA) application under review with European Medicines Agency (EMA) -- -- Ongoing clinical trials with avacopan in C3 Glomerulopathy (C3G)

MOUNTAIN VIEW, Calif. , May 02, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that the Company's first quarter 2018 financial results will be released after market close on Wednesday, May 9, 2018 . ChemoCentryx executive management will host a conference call and

MOUNTAIN VIEW, Calif. , April 11, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced the presentation of positive safety, efficacy and quality of life results from the Company’s successfully completed Phase II CLEAR and CLASSIC clinical trials of avacopan in the treatment